 price
thesi updat issu issu year ago print
would easili lead us conclud rest group would
post similarli lacklust result read-through group
nuanc uniqu outsiz exposur small
molecule/gener qa/qc workflow particularli china new
dynam highlight much larger peer chang mix
consum end market much balanc
perspect contrast harken back legaci tool cyclic
pure-play technology/end market exposur thu
like see tough like
even extent key differ
group growth perspect
mention player buy way higher growth market thu
question long maintain share multipl
without strateg chang exist busi market
forgiv compani print in-lin quarter maintain
guidanc especi trade today market
reaction surpris
key question investor lower guid
hope de-risk year low end certainli seem fair
paid short sweat support massiv buy-back
kudo moxi regard buy-back still one
biggest war-chest per market cap among peer mgmt decis
either buy share acquir higher growth market
buy-back certainli welcom repo see
repo fix appar structur problem busi
comp peer strateg move certainli believ management
chops/desir seri tuck-in la agil
actual envis day talk one tool
consolid remain sidelin given seen
movi expect mani short book profit avoid
upcom buy-back howev enough get us
excit upgrad especi given long-term
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
expect china eu bounc back cours year howev china pharma expect
mute seen past
lower gm vs prior
lower ep vs prior
rest fy guid unchang
tax better tax off-set rest yr
mani macro hw go complet bounce-back
moder increas expens
china biggest downsid surpris manag forecast model normal start
weak mostli due small molecul gener pharma adopt plan
food test weak due shift ministri see impact
eu weak pharma industri due budget delay ahead brexit
 lone bright spot among end market saw strength across geographi
strength pharma india
pharma overal mute due strength larg molecul off-set weak small molecule/gener
us due industri strength off-set pharma weak
bioaccord new product help acceler growth modest contribut
market develop stori take time shake
strong interest bioaccord
work net debt capit structur
mass spec pressur
ta instrument weak driven china eu
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin april
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
